Enhanced activated T cell subsets in prostate cancer patients receiving iodine-125 low-dose-rate prostate brachytherapy

  • Authors:
    • Makoto Kubo
    • Takefumi Satoh
    • Hiromichi Ishiyama
    • Ken-Ichi Tabata
    • Hideyasu Tsumura
    • Shoko Komori
    • Masatsugu Iwamura
    • Shiro Baba
    • Kazushige Hayakawa
    • Toshihiko Kawamura
    • Fumiya Obata
  • View Affiliations

  • Published online on: November 13, 2017     https://doi.org/10.3892/or.2017.6095
Metrics: PDF 0 views | HTML 0 views
0

Abstract

Radiotherapy (RT) is one of the most important treatments for prostate cancer. Although RT can kill cancer cells through direct and indirect effects of radiation, it occasionally induces an abscopal effect whereby localized radiation treatment is associated with elimination of metastatic cancer at a distance from the irradiated area. Thus, RT may induce an effective antitumor immune response, although the mechanism involved has remained unclear. The present was designed to evaluate this effect of RT in 36 patients with prostate cancer who provided informed consent prior to enrollment in this clinical trial. Peripheral blood samples were collected periodically after low-dose-rate (LDR) prostate brachytherapy, and lymphocyte subsets were analyzed by flow cytometry. The proportion of activated T cells (CD3+HLA-DR+, CD4+HLA-DR+ and CD8+HLA-DR+) in peripheral blood revealed a gradual and bimodal increase after LDR brachytherapy, whereas memory CD8+ T cells bimodally decreased after treatment. The ratios of activated T cells and regulatory T cells gradually increased after the treatment. Thus, LDR brachytherapy was demonstrated to induce effective immune responses in patients. This increase of activated T cells may contribute to maintenance of remission and reduction of relapse rates.

Related Articles

Journal Cover

Print ISSN: 1021-335X
Online ISSN:1791-2431

2016 Impact Factor: 2.662
Ranked #31/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kubo, M., Satoh, T., Ishiyama, H., Tabata, K., Tsumura, H., Komori, S. ... Obata, F. (1899). Enhanced activated T cell subsets in prostate cancer patients receiving iodine-125 low-dose-rate prostate brachytherapy. Oncology Reports, 0, 0-0. https://doi.org/10.3892/or.2017.6095
MLA
Kubo, M., Satoh, T., Ishiyama, H., Tabata, K., Tsumura, H., Komori, S., Iwamura, M., Baba, S., Hayakawa, K., Kawamura, T., Obata, F."Enhanced activated T cell subsets in prostate cancer patients receiving iodine-125 low-dose-rate prostate brachytherapy". Oncology Reports 0.0 (1899): 0-0.
Chicago
Kubo, M., Satoh, T., Ishiyama, H., Tabata, K., Tsumura, H., Komori, S., Iwamura, M., Baba, S., Hayakawa, K., Kawamura, T., Obata, F."Enhanced activated T cell subsets in prostate cancer patients receiving iodine-125 low-dose-rate prostate brachytherapy". Oncology Reports 0, no. 0 (1899): 0-0. https://doi.org/10.3892/or.2017.6095